Company intelligence / Profile preview
Centenara Labs
Schlieren, Zurich, Switzerlandcentenara.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
EA-2353 (Retinitis Pigmentosa) has completed Phase 1/2a demonstrating safety and signs of efficacy; dry-AMD program has IND clearance, clinical entry planned for 2025. Antibody and telomere programs show promising preclinical and IND-enabling data. Five first-in-class targets identified in early discovery for fibrosis, senescence, oncology, and aging
- Therapeutic areas
- NephrologyOphthalmologyPulmonologyNeurologyMetabolic DisordersOncology
- Modalities
- Small moleculeAntibodyCombination therapyDrug combinationPlatform company across multiple modalities
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Strategic pharma partnerships sought; specific names not publicly disclosed
Beyond the preview
Go deeper on Centenara Labs.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Centenara Labs.